MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Pancreas, Pancreatic
Tango Therapeutics, Inc. (NASDAQ:TNGX)*
Organization & Developments: Tango Therapeutics
Parents
Tango Therapeutics, Inc. (NASDAQ:TNGX)*
Children
2020: Tango Therapeutics Adds $175M, Deal Turns Partner Gilead Into Investor
2022: Early clinical-stage biotechnology concern focused on the development of therapies that target tumor suppressor gene loss in defined populations with high unmet medical need.
2022: Tango Therapeutics: Behind The Recent Momentum_ seekingalpha.com
2023: Circling Bank On Tango Therapeutics (NASDAQ:TNGX)
2024: Tango has last dance with PRMT5 inhibitor, pirouettes into embrace with 2 sibling molecules
2024: Tango Therapeutics Must Produce Its Own Data To Justify Its Valuation_seekingalpha.com
2024: Tango Therapeutics Reports 43% Response Rate in Cancer Trial, Secures $293M Cash Runway
2024: Tango Therapeutics: Making Its Way Into Clinic With 4 Innovative Cancer Drugs
2024: Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts
2025: Tango Therapeutics Highlights Breakthroughs in Cancer Treatmentwww.tipranks.com
2025: Tango Therapeutics: Chance For A Short Squeeze
2025: Tango Therapeutics: PRMT5 Data Readout Due In 2025 Is Critical
2026: 'Synthetic lethality' could trigger another round of biotech M&A | STAT
Jumps
Finance & Acquisitions: Tango Therapeutics
Key People: Tango Therapeutics